drugset / Trial / NCT00145886

rhPTH Therapy for Low Turnover Bone Fragility

NCT00145886

Phase 1 Terminated 2 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.

Timeline

Start
2003-02
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic

Indications